Proprietary Adjuvant System Induces Improved Immune Response vs. Conventional Formulation

Overview:

GlaxoSmithKline’s (GSK) candidate vaccine for the prevention of cervical cancer formulated with proprietary AS04 adjuvant system claims to have better immune response compared with the vaccine formulated with conventional aluminum salt adjuvant.